GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles

• Status: Recruiting
• Trial end date: 2021-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

Evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist (GnRHa) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (ICSI) following GnRH antagonist protocol

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Triptorelin Pamoate

Criteria

Inclusion Criteria:

• Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRH antagonist.

Exclusion Criteria:

• Moderate or severe endometriosis.

• Hydrosalpinx.

• Uterine abnormalities.

• Myoma.

• Previous uterine surgery.